DOMH

SEC Filing Summary: Spherix Incorporated (Form 10-Q)

Business Context and Reporting Period

This filing covers the quarterly period ended June 30, 2010. The registrant is Spherix Incorporated (Note: The input metadata referenced "Dominari Holdings Inc.", but the filing text explicitly identifies the company as Spherix Incorporated). Spherix operates through two segments: Biospherics, which develops proprietary products (specifically D-tagatose for diabetes and triglycerides), and Health Sciences, which provides technical and regulatory consulting services. The company is classified as a smaller reporting company.

Key Financial Metrics

Cash Flow: Net cash used in operating activities for the six months ended June 30, 2010, was $4.69 million. Net cash provided by investing activities was $250,003, primarily from the maturity of short-term investments.

Material Changes vs. Prior Period

• Revenue: Revenue for the three months ended June 30, 2010, decreased slightly to $327,139 from $332,241 in the prior year period. For the six-month period, revenue decreased to $659,430 from $692,911. All revenue is derived from the Health Sciences segment; the Biospherics segment generated no revenue.
• Operating Expenses: Total operating expenses increased significantly. For the three months ended June 30, 2010, expenses rose to $2.89 million from $1.89 million in 2009. This was driven by a $411,000 increase in R&D expenses (related to concluding Phase 3 trial procedures) and a $581,000 increase in Selling, General, and Administrative (SG&A) expenses (related to commercialization efforts).
• Liquidity: Cash and cash equivalents decreased from $9.03 million at December 31, 2009, to $4.59 million at June 30, 2010. Working capital declined from $7.7 million to $3.0 million.

Guidance, Outlook, and Risks

Strategic Shift: Management has terminated the safety portion of its Phase 3 diabetes clinical trial due to the high cost of FDA approval for diabetes drugs. The company is actively seeking a pharmaceutical partner to continue diabetes development and is shifting R&D focus to explore D-tagatose as a treatment for high triglycerides.

Capital Requirements: The company expects to expend its current cash reserves of approximately $4.7 million within the next six months. It estimates a need for $7 million to $9 million over the next 12 months to support operations. A Form S-1 registration statement was filed on July 2, 2010, to raise additional capital.

Risks and Contingencies:

• Liquidity Risk: Failure to secure additional financing could force the company to delay or abandon clinical development plans.
• Development Risk: There is no assurance that the triglycerides program will succeed or that a strategic partner will be found for the diabetes program.
• Regulatory Risk: The company has never filed a New Drug Application (NDA) and faces significant regulatory hurdles.
• Listing Risk: The company must maintain NASDAQ listing standards, including a minimum bid price of $1.00 and shareholders' equity of $2.5 million. Stockholders' equity was $2.6 million as of June 30, 2010.

Investor Verification Checklist

• Verify the status and effectiveness of the Form S-1 registration statement filed on July 2, 2010, for raising capital.
• Confirm the timeline and results of the Phase 3 diabetes trial efficacy data expected by mid-September 2010.
• Monitor cash burn rate against the projected $7–$9 million expenditure requirement for the next 12 months.
• Check for any updates regarding the search for a pharmaceutical partner for the diabetes program.
• Review compliance with NASDAQ listing requirements, specifically the minimum bid price and equity thresholds.